You've probably heard of DNA sequencing, but you might not realize that a massive legal and scientific war was fought over a microscopic hole found in a bacterium. Specifically, Mycobacterium smegmatis porin A. Or, as the patent lawyers call it, MspA. If you look into the mspa nanopore sequencing patent application us records, you aren't just looking at boring legal filings. You're looking at the blueprint for how we now read the code of life in real-time.
It’s wild.
👉 See also: Who is the inventor of the iPhone? The messy truth behind the glass
For years, the world used "sequencing by synthesis." Basically, you’d build a DNA strand and take photos of glowing colors. It worked, but it was slow, expensive, and required huge machines. Then researchers realized they could just pull a DNA strand through a tiny hole—a nanopore—and measure the electrical change.
But there was a problem. The holes they were using, like Alpha-hemolysin ($\alpha$HL), were too long. It was like trying to read a newspaper through a tunnel; the signal was blurry because too many DNA bases were in the hole at once.
The MspA Breakthrough
That’s where MspA comes in. MspA is a protein pore with a short, narrow "constriction zone." This shape is the holy grail for sequencing. Because the "sensing" part of the pore is so short, you can actually distinguish between individual nucleotides ($A, T, C, G$) as they zip through.
The mspa nanopore sequencing patent application us filings, particularly those linked to the University of Washington and later licensed by giants like Oxford Nanopore Technologies (ONT) or Illumina, represent a pivot point in biotech. Specifically, U.S. Patent No. 8,673,550 and its related applications changed the game. These patents don't just cover the protein itself; they cover the mutant versions.
Nature didn't make MspA perfect for sequencing. The "wild-type" version has a negative charge that actually repels DNA. Scientists had to go in and swap out amino acids—specifically replacing negatively charged residues with neutral or positive ones—to "suck" the DNA through.
Why the Patents Mattered So Much
Patent law in the U.S. is a nightmare for biotech. You can't just patent something found in nature. That's the Myriad Genetics rule. However, you can patent a modified, non-naturally occurring version of a protein that performs a specific utility.
The mspa nanopore sequencing patent application us history is a saga of showing that these engineered pores were "markedly different" from what you’d find in a random soil sample.
The University of Washington researchers, including Jens Gundlach and Derrington, filed the foundational work. They showed that by using MspA, they could get a signal-to-noise ratio that made $\alpha$HL look like a joke. They basically turned a biological channel into a high-precision digital sensor.
It Wasn't Just One Patent
It was a cluster.
👉 See also: Designing Data Intensive Applications: What Most People Get Wrong
You had applications covering the pore structure, the "motor" proteins (helicases) that slow the DNA down so it doesn't fly through too fast, and the signal processing algorithms. Without the motor protein, DNA moves through the pore at roughly one million bases per second. That's way too fast for any computer to read. The patent applications describe a "ratcheting" system where an enzyme sits on top of the MspA pore and feeds the DNA through one base at a time.
Imagine a bead on a string. Now imagine trying to count the beads while they are shot out of a pneumatic tube. Impossible. The motor protein is the hand that pulls the string slowly, and MspA is the eye that sees each bead clearly.
The Legal Friction
Illumina and Oxford Nanopore haven't always been friends. In fact, they’ve been in and out of court more times than a repeat offender. A lot of the friction centered on who had the rights to use these specific pores.
In 2016, Illumina sued ONT, alleging that ONT’s MinION and PromethION devices infringed on patents related to MspA. They eventually settled, but it highlighted a key truth: MspA was the "killer app" of the nanopore world. Even though researchers are now looking at synthetic solid-state pores made of silicon nitride or graphene, the biological MspA pore remains the gold standard for commercial accuracy.
The Tech Specifics
What makes MspA so special in these patent applications? It’s the geometry.
- The "vestibule" is wide.
- The "constriction" is roughly 1.2 nanometers.
- The sensing region is only about 0.6 nanometers long.
Because $0.6$ nanometers is roughly the distance of two nucleotides, the electrical current (ionic current) is modulated primarily by just a couple of bases. This makes the "wiggles" in the data much easier to translate into a genetic sequence using neural networks.
Honestly, the math behind this is staggering. We are talking about measuring picoampere ($10^{-12}$ A) changes in current. If you’ve ever used a handheld MinION sequencer to test for Ebola in the field or sequence a genome in space, you are using the direct descendants of the mspa nanopore sequencing patent application us filings.
Misconceptions About the Patent Landscape
People often think a patent means one company "owns" a protein. That’s not quite it. In the U.S., these patents cover the method of using the pore for sequencing and the specific mutations that make it work.
If you found a new pore in a deep-sea vent that worked better than MspA, you could patent that too. But MspA was the first one that actually worked well enough to be commercialized.
Also, it's not just about DNA. Recent applications have focused on using these pores for protein sequencing. Reading amino acids is way harder than reading nucleotides because there are 20 of them instead of 4, and they don't have a uniform charge. But the MspA architecture is being tweaked to try and solve that, too.
Real-World Impact
Why should you care about a 20-year-old patent application?
✨ Don't miss: iPhone 16 Pro Unlocked: What Most People Get Wrong About Buying Direct
Because it's the reason we can sequence a human genome for under $200 today. It’s the reason we can do "long-read" sequencing. Traditional sequencing breaks DNA into tiny bits (150 bases) and tries to stitch them back together like a billion-piece puzzle. Nanopore sequencing using MspA can read pieces that are 100,000 bases long.
It makes the "un-sequenceable" parts of the genome—the repetitive regions that cause many diseases—visible for the first time.
What’s Next for Nanopore Patents?
The original MspA patents won't last forever. As they expire, we might see a "generic" nanopore market, similar to how we have generic drugs. But the industry is already moving toward CsgG pores and other biological structures that offer even better stability.
However, MspA will always be the "OG." It proved that biological pores were viable.
Actionable Insights for the Tech-Curious
If you are a researcher, a patent clerk, or just someone interested in the future of biotech, here is what you need to keep an eye on regarding the mspa nanopore sequencing patent application us and its successors:
- Check the USPTO Public PAIR: You can look up the "file wrapper" for patents like 8,673,550. It’s a goldmine. You can see the actual arguments between the patent examiners and the scientists. It reveals exactly what the "novel" part of the tech is.
- Look at "Pore-Forming Toxins": If you're looking for the next MspA, keep an eye on research involving FraC or Lysenin. These are the new frontier of biological pores being patented right now.
- Focus on the "Signal-to-Noise": The value of any nanopore patent is entirely dependent on its ability to produce a clean signal. If a patent application doesn't show a clear differentiation between the four bases, it's basically worthless in the real world.
- Watch for Protein Sequencing: The next big patent war won't be about DNA. It will be about who can use an MspA-style pore to identify single proteins in a mixture. That is the "proteomics" revolution, and it's where the money is headed.
The MspA story is a reminder that big things—like the future of medicine—often hang on the tiniest of details. In this case, a hole 100,000 times smaller than a human hair.